852 related articles for article (PubMed ID: 19748990)
1. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
2. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
[TBL] [Abstract][Full Text] [Related]
3. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
4. The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma.
Ishida T; Iida S; Akatsuka Y; Ishii T; Miyazaki M; Komatsu H; Inagaki H; Okada N; Fujita T; Shitara K; Akinaga S; Takahashi T; Utsunomiya A; Ueda R
Clin Cancer Res; 2004 Nov; 10(22):7529-39. PubMed ID: 15569983
[TBL] [Abstract][Full Text] [Related]
5. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
6. Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse model.
Masaki A; Ishida T; Suzuki S; Ito A; Mori F; Sato F; Narita T; Yamada T; Ri M; Kusumoto S; Komatsu H; Tanaka Y; Niimi A; Inagaki H; Iida S; Ueda R
J Immunol; 2013 Jul; 191(1):135-44. PubMed ID: 23733874
[TBL] [Abstract][Full Text] [Related]
7. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
8. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
[TBL] [Abstract][Full Text] [Related]
9. In vivo assay of human NK-dependent ADCC using NOD/SCID/gammac(null) (NOG) mice.
Shiokawa M; Takahashi T; Murakami A; Kita S; Ito M; Sugamura K; Ishii N
Biochem Biophys Res Commun; 2010 Sep; 399(4):733-7. PubMed ID: 20696130
[TBL] [Abstract][Full Text] [Related]
10. Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody.
Eisenthal A; Cameron RB; Rosenberg SA
J Immunol; 1990 Jun; 144(11):4463-71. PubMed ID: 2111349
[TBL] [Abstract][Full Text] [Related]
11. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
12. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene.
King M; Pearson T; Shultz LD; Leif J; Bottino R; Trucco M; Atkinson MA; Wasserfall C; Herold KC; Woodland RT; Schmidt MR; Woda BA; Thompson MJ; Rossini AA; Greiner DL
Clin Immunol; 2008 Mar; 126(3):303-14. PubMed ID: 18096436
[TBL] [Abstract][Full Text] [Related]
13. The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma.
Ishida T; Ishii T; Inagaki A; Yano H; Kusumoto S; Ri M; Komatsu H; Iida S; Inagaki H; Ueda R
Leukemia; 2006 Dec; 20(12):2162-8. PubMed ID: 17039235
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
Flavell DJ; Warnes SL; Noss AL; Flavell SU
Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
[TBL] [Abstract][Full Text] [Related]
15. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
Flavell DJ; Warnes S; Noss A; Flavell SU
Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737
[TBL] [Abstract][Full Text] [Related]
16. An in vivo model of priming of antigen-specific human CTL by Mo-DC in NOD/Shi-scid IL2rgamma(null) (NOG) mice.
Inoue M; Senju S; Hirata S; Irie A; Baba H; Nishimura Y
Immunol Lett; 2009 Sep; 126(1-2):67-72. PubMed ID: 19682495
[TBL] [Abstract][Full Text] [Related]
17. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome.
Yano H; Ishida T; Inagaki A; Ishii T; Ding J; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Clin Cancer Res; 2007 Nov; 13(21):6494-500. PubMed ID: 17975162
[TBL] [Abstract][Full Text] [Related]
18. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
19. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma.
Niwa R; Shoji-Hosaka E; Sakurada M; Shinkawa T; Uchida K; Nakamura K; Matsushima K; Ueda R; Hanai N; Shitara K
Cancer Res; 2004 Mar; 64(6):2127-33. PubMed ID: 15026353
[TBL] [Abstract][Full Text] [Related]
20. Long-term human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells.
André MC; Erbacher A; Gille C; Schmauke V; Goecke B; Hohberger A; Mang P; Wilhelm A; Mueller I; Herr W; Lang P; Handgretinger R; Hartwig UF
J Immunol; 2010 Sep; 185(5):2710-20. PubMed ID: 20668220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
